PTCT CLUSTER SEC Filing Analysis

Latest settled — T+20d

PTCT ▼ -6.11% at T+20d

SHORT call ✓ call won +6.11% · α vs SPY +15.83% · entry $68.75 → $64.55

Next anchor: T+60d in 5w

Currently $71.02 · -3.30% from $68.75 entry (call sign-flipped)

Entry anchored
Mar 31, 03:59 PM ET
via Databento tick

T+1d

-1.43%

call +1.43% · α +1.50%

$67.77

settled 7w ago

T+5d

+3.05%

call -3.05% · α +0.71%

$70.85

settled 6w ago

T+20d

-6.11%

call +6.11% · α +15.83%

$64.55

settled 21d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Three senior executives at PTC Therapeutics sold shares in a concentrated 7-day window, including a $2.71M open-market sale by the Chief Technical Operations Officer. The total value of open-market sales reached $2.83M, representing 0.05% of the company's $5.8B market cap, with additional non-cash derivative exercises.

Key Financial Metrics

Direction

selling

Total Value

$2.8M

Insiders

3

Actionable Insight

The cluster of sales by C-suite executives, particularly the large $2.71M sale by the Chief Technical Operations Officer, suggests potential lack of confidence in near-term valuation or upcoming catalysts. While the total dollar amount is modest relative to market cap, the concentration and seniority of sellers elevate concern. Monitor for upcoming earnings, regulatory decisions, or pipeline updates that may have prompted this activity.

Key Facts

Almstead Neil Gregory (Chief Technical Operations Officer) sold 39,400 shares at $68.89 for $2.71M in an open-market transaction.
Boulding Mark Elliott (Exec VP and CLO) sold 822 shares at $68.91 for $56,644 and separately exercised 4,530 derivative securities (2,265 at $0, 2,265 at $39.42), resulting in $89,286 cash outlay.
Golden Lee Scott (EVP & Chief Medical Officer) sold 829 shares at $67.99 for $56,364.
Total open-market sale value: $2.83M over 7 days.
All transactions occurred between 2026-04-01 and 2026-04-06.

Financial Impact

$2.83M in net open-market sales by insiders over 7 days, representing 0.05% of $5.8B market cap

insider sentimentshareholder confidence

Risk Factors

Insider selling can signal negative sentiment, especially when concentrated among top executives.
Potential for negative market perception despite relatively small dollar size relative to market cap.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

Document	Accession Number
CLUSTER Data (Synthetic)	cluster-PTCT-1775683243096

7 reports for PTCT

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PTCT — sortable, filterable
	Type				Now
May 19, 2026 1d ago	Insider Cluster NEUTRAL ★ 2/10	—	awaiting T+20	—	—
May 15, 2026 5d ago	Insider Cluster NEUTRAL ★ 2/10	—	awaiting T+20	—	—
Apr 28, 2026 22d ago	8-K BULLISH ★ 6/10	—	awaiting T+20	—	—
Apr 20, 2026 4w ago	DEFA14A NEUTRAL ★ 3/10	$70.63 $70.15	▼ −0.68%	▼ −5.59%	$71.02 (+0.55%)
Apr 1, 2026 7w ago	Insider Cluster BEARISH ★ 5/10	$68.75 $64.55	▲ +6.11%	▲ +15.83%	$71.02 (−3.30%)
Mar 5, 2026 10w ago	Insider Cluster NEUTRAL ★ 3/10	$63.33 $67.77	▲ +7.01%	▲ +10.80%	$71.02 (+12.14%)
Mar 5, 2026 10w ago	Insider Cluster BEARISH ★ 6/10	$63.33 $67.77	▼ −7.01%	▼ −10.80%	$71.02 (−12.14%)

US Market Status

Market Closed — Opens Thu (< 1m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access